Anebulo Pharmaceuticals, Inc.

NasdaqCM ANEB

Anebulo Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Anebulo Pharmaceuticals, Inc. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: ANEB

Anebulo Pharmaceuticals, Inc.

CEO	Mr. Richard Anthony Cunningham
IPO Date	May 7, 2021
Location	United States
Headquarters	1415 Ranch Road 620 South
Employees	2
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Key trends

Past 5 years